Form 4: Allogene Therapeutics Director Elizabeth Barrett Acquires Stock Options

Director Elizabeth Barrett acquired stock options for Allogene Therapeutics, Inc. on June 5, 2024.

Summary

• On June 5, 2024, Elizabeth A. Barrett, a director of Allogene Therapeutics, Inc., acquired stock options.
• The stock options grant the right to buy 191,082 shares of common stock at an exercise price of $2.44.
• The options vest in 12 equal monthly installments and expire on June 5, 2034.
• Following the transaction, Barrett directly owns 191,082 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The impact depends on the broader context of the company's performance and market conditions.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the biotech industry.
• The vesting schedule of 12 months is fairly standard.
• The exercise price is a key factor, and its relationship to the current market price would be relevant for assessing the value of the grant.

Stakeholder Impact

• The acquisition of stock options by a director can influence shareholder sentiment, potentially signaling confidence in the company's prospects.

Key Dates